JNJ.DE Johnson & Johnson
P/E
30.337748
Forward P/E
--
Price/Sales
5.6303344
Beta
0.235
Div Yield
0.021%
Market Cap
--
Company Analysis
Latest News
Johnson & Johnson’s TALVEY Beats Standard Care in Multiple Myeloma Trial
Johnson & Johnson announced Phase 3 MonumenTAL-3 study results for its multiple myeloma therapy at the 2026 European Hematology Association (EHA) Annual...
Johnson & Johnson's Anemia Drug IMAAVY Shows Positive Results in Late-Stage Trial
Johnson & Johnson announced positive results from a pivotal Phase 2/3 study of its drug, IMAAVY (nipocalimab), for warm autoimmune hemolytic anemia (wAIHA)....